Contact UsCareersNewsScienceContact Us
Access & Assistance Made Easy Via Pfizer PAP India AppHomeAbout usPatient CenticityAccess & Assistance Made Easy Via Pfizer PAP India App

Pfizer India is leading the race in making state-of-the-art healthcare more accessible, with innovative drugs and treatments at the forefront. In line with this Pfizer has launched the ‘Pfizer PAP India’—a mobile application designed to ease and fast track enrolment to Pfizer's Patient Access Programs (PAP). At present Pfizer runs over 10 programs supporting patients with Pfizer treatments. This mobile application is an extension of Pfizer’s endeavour to amalgamate innovation in healthcare.

The ‘Pfizer PAP India’ mobile application is now available on both iOS and Android platforms. The application has been carefully designed to support patients who would like to be a part of Pfizer's Patient Access Program. This program offers eligible patients therapy assistance, based on a valid prescription by the treating physician and the submission of other required documents by the patient. Once registered on it, the app offers them a one-stop solution to elevate their treatment journey, at the touch of a button.

Using the application is simple, patients can enrol in the program by uploading the required documents on the portal. The app is easy to navigate, enables hassle-free documentation, facilitates easy fast-track enrolment and is safe for all our users.

Commenting on the launch of this app, Satyen Amin, Director- Commercial Channel and Market Access, Pfizer India said “Patients are at the heart of what we do! Improving access to our medicines via PAPs and providing information and support services ecosystem to help patients follow through in their treatment journey is our goal.”

Speaking about the launch, Dr Rahul Bhargava (Director & HOD - Department of Hematology & BMT Fortis hospital Gurgaon) said, "We believe that access to medicines and medication adherence determines treatment effectiveness. These are some of the most useful interventions for improving health outcomes. However, this is possible only through regular patient monitoring and access to innovative medicines. Through PAP app, patients can now seamlessly navigate their health journey on a single platform where they are enrolled. We are certain that this endeavour will benefit the healthcare ecosystem as well as the patients.”

PAP is executed by Tata 1 MG (MediAngels by TATA 1MG) on behalf of Pfizer India. Commenting on this collaboration Prashant Tandon, Cofounder & CEO, Tata 1 MG said “We are proud of our association with Pfizer which has gone a step further with the launch of Pfizer PAP India mobile application. For us at Tata 1 MG, Cancer Care is not just about providing services to patients but more importantly helping them navigate the journey better, with compassion and care. This app shall further enable patients to ease their access to medication and services through a self-serve platform. Now, patients will be able to avail of all the applicable services directly and seamlessly by using the mobile application. Congratulations to the Pfizer and 1 MG teams for working collaboratively and continuing to innovate and enhance the patient experience. This is yet another step closer to creating a better cancer journey for patients who need utmost care,”

To date, Pfizer has touched thousands of patient lives across the country through ongoing Patient Support Programs.

About UsOur ScienceOur Community EffortsYour Health Career-Seekers News & MediaHealthcare ProfessionalsContact UsTerms And ConditionsPrivacy PolicyAdverse Event ReportingCopyright © 2002- 2022 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of  India and strictly only for informational, educational, academic and/or research purposes and is not intended to substitute for professional medical advice, diagnosis or treatment. While due care and caution has been taken to ensure that the content here is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information here. You may report an adverse event related to Pfizer products by emailing us at [email protected] or via Fax at: 000800100-5961 / +91-22 3919-771.